Acetaminophen and myocardial infarction in dogs

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 287, Issue 5 56-5, 2004, Pages

  Merrill, Gary F ^a   Rork, Tyler H ^a   Spiler, Norell M ^a   Golfetti, Roseli ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Area at risk; Canine myocardium; Electron microscopy; Heart disease

Indexed keywords

PARACETAMOL;

ANIMAL MODEL; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; EPICARDIUM; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART RATE; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; MOLECULAR WEIGHT; NECROSIS; NONHUMAN; PH; PRIORITY JOURNAL; REDUCTION; RISK FACTOR;

ACETAMINOPHEN; ANIMALS; CARDIOTONIC AGENTS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; DOGS; ELECTROCARDIOGRAPHY; HEART RATE; HEMODYNAMIC PROCESSES; MALE; MICROSCOPY, ELECTRON; MYOCARDIAL INFARCTION; MYOFIBRILS; NECROSIS; VENTRICULAR FUNCTION;

EID: 7244258751     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00565.2004     Document Type: Article

References (44)

1. Altavilla D, Deodato B, and Campo GM, IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kB and reduces the inflammatory response in myocardial ischemia-reperfusion injury. Cardiovasc Res 47: 515-528, 2000.
2. Amsterdam EA, Stahl GL, and Pan HL. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 268: H448-H457, 1995.
3. Bolli R, Jeroudi MO, and Patel BS. Marker reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial stunning is a manisfestation of reperfusion injury. Circ Res 65: 607-622, 1989.
4. 2 synthases. Proc Natl Acad Sci USA 99: 7130-7135, 2002.
5. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, and Hasen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349: 1595-1604, 2003.
6. Buerke M, Murohara T, and Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation 91: 393-402, 1995.
7. Chou TM and Greenspan P. Effect of acetaminophen n the myeloperoxidase-hydrogen peroxide-nitrite mediated oxidation of LDL. Biochim Biophys Acta 1581: 57-63, 2002.
8. Dai W and Kloner RA. Effects of acetaminophen on myocardial infarct size in rats. J Cardiovasc Pharmacol Therapeut 8: 277-284, 2003.
9. Downey HF, Merrill GF, Yonekura S, Watanabe N, and Jones CE. Adenosine deaminase attenuates norepinephrine-induced coronary functional hyperemia. Am J Physiol Heart Circ Physiol 254: H417-H424, 1988.
10. Galang N, Sasaki H, and Maulik N. Apoptotic cell death during ischemia/reperfusion and its attenuation by antioxidant therapy. Toxicology 148: 111-118, 2000.
11. Golfetti R, Rork T, and Merrill GF. Chronically-administered acetaminophen and the ischemia-reperfused myocardium. Exp Biol Med 228: 674-682, 2003.
12. Golfetti R, VanDyke K, Rork T, Spiler N, and Merrill GF. Acetaminophen in the postischemia reperfused myocardium. Exp Biol Med 227: 1031-1038, 2002.
13. Gonon AT, Gourine AV, and Pernow J. Cardioprotection from ischemia and reperfusion injury by an endothelin A-receptor antagonist in relation to nitric oxide production. J Cardiovasc Pharmacol 36: 405-412, 2000.
14. Grover GJ, Dzwonczyk S, and Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 27: 1613-1618, 1993.
15. Hale SL and Kloner RA. Acetaminophen and experimental acute myocardial infarction. Cardiovasc Drugs Ther 18: 121-125, 2004.
16. Hatori N, Tadokoro H, and Satomura K. Beneficial effects of coronary venous retroinfusion but not left atrial administration of superoxide dismutase on myocardial necrosis in pigs. Eur Heart J 12: 442-450, 1991.
17. Herzog WM, Vogel RA, and Schlossberg ML. Short-term, low-dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size. Int J Cardiol 59: 21-27, 1997.
18. Jalowy A, Schultz R, Dorge H, Behrends M, and Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. Am Coll Cardiol 32: 1787-1796, 1998.
19. Johnson GI, Tsao PC, and Lefer AM. Cardioprotective effects of authentic nitric oxide in myocardial ischemia and reperfusion. Crit Care Med 19: 244-252, 1991.
20. Jolly SR, Kane WJ, Bailie MB, Abrams GD, and Lucchesi BR. Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res 54: 277-284, 1984.
21. Jordan JE, Zhao ZQ, Sato H, Taft S, and Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation, and coronary endothelial adherence. J Pharmacol Exp Ther 280: 301-309, 1997.
22. Jordan JE, Zhao ZQ, and Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res 43: 860-878, 1999.
23. Lefer AM and Lefer DJ. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischemia-reperfusion. Cardiovasc Res 32: 743-751, 1996.
24. Lefer DJ, Nakanishi K, Johnston WE, and Vinten-Johansen J. Antineutrophil and myocardial protecting action of a nitric oxide donor after acute myocardial ischemia and reperfusion in dog. Circulation 88: 2337-2350, 1993.
25. Linz W, Albus U, and Crause P. Dose-dependent reduction of myocardial infarct mass in rabbits by NHE-1 inhibitor cariporide (HOE642). Clin Exp Hypertens 20: 733-749, 1998.
26. Manor D, Williams S, Ator R, Bryant K, and Scheel KW. Reduced collateral perfusion is a direct consequence of elevated right atrial pressure. Am J Physiol Heart Circ Physiol 267: H1151-H1156, 1994.
27. McHugh NA, Cook SW, Schairer JA, and Merrill GF. Ischemia and reperfusion induced ventricular arrhythmias in the dog: effects of estrogen. Am J Physiol Heart Circ Physiol 268: H2569-H2573, 1995.
28. Merrill GF. Acetaminophen (paracetamol) and injury in the cardiovascular system. Vasc Dis Prev 1: 123-132, 2004.
29. Merrill GF. Acetaminophen and low-flow myocardial ischemia: efficacy and antioxidant mechanisms. Am J Physiol Heart Circ Physiol 282: H1341-H1349, 2002.
30. Merrill GF, Downey HF, and Jones CE. Adenosine deaminase attenuates canine coronary vasodilation during systemic hypoxia. Am J Physiol Heart Circ Physiol 250: H579-H583, 1986.
31. Merrill GF and Goldberg E. Antioxidant properties of acetaminophen and cardioprotection. Basic Res Cardiol 96: 422-429, 2001.
32. Merrill GF, VanDyke K, McConnell P, and Powell SR. Coronary and myocardial effects of acetaminophen: protection during ischemia and reperfusion. Am J Physiol Heart Circ Physiol 280: H2631-H2638, 2001.
33. + exchange inhibitor, HOE642: difference from preconditioning in the role of protein kinase C. J Am Coll Cardiol 29: 693-701, 1997.
34. Mocanu MM, Baxter GF, and Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol 130: 197-200, 2000.
35. Nakamoto K, Kamisaki Y, Wada K, Kawasaki H, and Itoh T. Protective effect of acetaminophen against acute gastric mucosal lesions induced by ischemia-reperfusion in the rat. Pharmacology 54: 203-210, 1997.
36. Norton ED, Jackson EK, Turner MB, Virmani R, and Forman MB. The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am Heart J 123: 332-338, 1992.
37. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, and Witztum JL. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86: 1372-1376.
38. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazer WA, Hoff HF, and Hazen SL. Macrophages scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 105: 1095-1108, 2000.
39. Riley RD, Sato H, and Zhao ZQ. Recombinant human complement C5a receptor antagonist reduces infarct size after surgical revascularization. J Thorac Cardiovasc Surg 120: 350-358, 2000.
40. Scheel KW, Banet M, Ott C, and Lehan PH. A quantitative approach to collateral and antegrade flows after coronary occlusion. Am J Physiol 222: 687-694, 1972.
41. Shimizu M, Wang QD, Sjoquist PO, and Ryden L. Angiotensin II type 1 receptor blockade with candesartan protects the porcine myocardium from reperfusion-induced injury. J Cardiovasc Pharmacol 32: 231-238, 1998.
42. Shimizu M, Wang QD, Sjoquist PO, and Ryden L. The lipid peroxidation inhibitor indenoindole H290/51 protects myocardium at risk of injury induced by ischemia-reperfusion. Free Radic Biol Med 24: 726-731, 1998.
43. Tadokora H, Miyazaki A, and Satomura K. Infarct size reduction with coronary venous retroinfusion of diltiazem in the acute occlusion/reperfusion porcine heart model. J Cardiovasc Pharmacol 28: 134-141, 1996.
44. Wang QD, Pernow J, Sjoquist PO, and Ryden L. Pharmacological possibilities for protection against myocardial reperfusion injury. Cardiovasc Res 55: 25-37, 2002.